Inhibition of Mast Cell Function and Proliferation by mTOR Activator MHY1485.
- Author:
Valeriya RAKHMANOVA
1
;
Mirim JIN
;
Jinwook SHIN
Author Information
- Publication Type:Brief Communication
- Keywords: Mast cells; High-affinity IgE receptor; Mechanistic target of rapamycin; MHY1485; Cell degranulation; Cell proliferation
- MeSH: Adaptive Immunity; Anaphylaxis; Asthma; Cell Degranulation; Cell Proliferation; Hypersensitivity; Immunoglobulin E; Interleukin-3; Interleukin-6; Mast Cells*; Peptide Initiation Factors; Phosphorylation; Ribosomal Protein S6 Kinases; Serine; Signal Transduction; Sirolimus; Tumor Necrosis Factor-alpha
- From:Immune Network 2018;18(3):e18-
- CountryRepublic of Korea
- Language:English
- Abstract: Mast cells integrate innate and adaptive immunity and are implicated in pathophysiological conditions, including allergy, asthma, and anaphylaxis. Cross-linking of the high-affinity IgE receptor (FcεRI) initiates diverse signal transduction pathways and induces release of proinflammatory mediators by mast cells. In this study, we demonstrated that hyperactivation of mechanistic target of rapamycin (mTOR) signaling using the mTOR activator MHY1485 suppresses FcεRI-mediated mast cell degranulation and cytokine secretion. MHY1485 treatment increased ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation, which are downstream targets of mTOR complex 1 (mTORC1), but decreased phosphorylation of Akt on mTOR complex 2 (mTORC2) target site serine 473. In addition, this activator decreased β-hexosaminidase, IL-6, and tumor necrosis factor α (TNF-α) release in murine bone marrow-derived mast cells (BMMCs) after FcεRI stimulation. Furthermore, MHY1485-treated BMMCs showed significantly decreased proliferation when cultured with IL-3. These findings suggested hyperactivation of mTORC1 as a therapeutic strategy for mast cell-related diseases.
